Furthermore, YY1 might positively regulate the expression of programmed death ligand 1 (PD-L1), whose expression is correlated with poor clinical response to cell-mediated anti-tumor therapy, through crosstalk between YY1 and PD-L1 signaling pathways 119-121. This evidence concerns the gene YY1 and neoplasm.